KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortization of Deferred ChargesAmortizatization of IntangiblesAmortizatization of IntangiblesAsset Writedowns and ImpairmentAsset Writedowns and ImpairmentCapital ExpendituresCapital ExpendituresCash from Discontinued OperationsCash from Discontinued OperationsCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Accured ExpensesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in IntangiblesChange in InventoryChange in InventoryChange in ReceivablesChange in ReceivablesChange in TaxesChange in TaxesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Exchange Rate EffectExchange Rate EffectFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesOther Working Capital ChangesShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationAccumulated Depreciation & AmortizationCost of RevenueEBIATGross ProfitLeasesLong-Term Debt RepaymentsMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)Receivables - NetReceivables - OtherShares IssuedShares OutstandingShares Outstanding
Ratios

Travere Therapeutics (TVTX) Long-Term Debt Repayments (2013 - 2022)

Travere Therapeutics posted quarterly Long-Term Debt Repayments of $211.3 million for Q1 2022, up 435.63% on a QoQ basis from $39.5 million in Q4 2018.

Travere Therapeutics (TVTX) has 6 years of Long-Term Debt Repayments data on file, last reported at $211.3 million in Q1 2022.

  • For the quarter ending Q1 2022, Long-Term Debt Repayments changed N/A year-over-year to $211.3 million; the trailing twelve-month figure through Dec 2022 stood at $211.3 million (changed N/A YoY), and the FY2025 full-year result was $68.9 million, changed N/A from the prior year.
  • Long-Term Debt Repayments for Q1 2022 stood at $211.3 million, up from $39.5 million in the prior quarter.
  • Across five years, Long-Term Debt Repayments topped out at $211.3 million in Q1 2022 and bottomed at $250000.0 in Q3 2018.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Long-Term Debt Repayments (Qtr)
1 Quantum Biopharma 961,148.99 Bn 961,148.98 Bn - -
2 Alterity Therapeutics 744,933.29 Bn 744,933.26 Bn - -
3 Legend Biotech 2,540.00 Bn 2,539.71 Bn 242.10 Mn -
4 Nanobiotix 2,199.85 Bn 2,199.78 Bn - -
5 Akari Therapeutics 1,635.88 Bn 1,635.88 Bn - -
6 Vertex Pharmaceuticals 111.32 Bn 104.07 Bn 2.59 Bn -
7 Evaxion A 62.56 Bn 62.54 Bn - -
8 Regeneron Pharmaceuticals 62.55 Bn 53.79 Bn 3.31 Bn -
9 Alnylam Pharmaceuticals 39.57 Bn 36.56 Bn 959.66 Mn -
10 Travere Therapeutics 4.14 Bn 4.06 Bn 102.38 Mn -

Historic Data

Download Data 🔒
DateValue
Mar 31, 2022 211.32 Mn
Mar 31, 2022 211.32 Mn
Dec 31, 2018 39.45 Mn
Dec 31, 2018 39.45 Mn
Sep 30, 2018 250,000.00
Sep 30, 2018 250,000.00
Jun 30, 2018 500,000.00
Jun 30, 2018 500,000.00
Sep 30, 2017 -500,000.00
Sep 30, 2017 -500,000.00
Jun 30, 2017 250,000.00
Jun 30, 2017 250,000.00
Mar 31, 2017 250,000.00
Mar 31, 2017 250,000.00
Dec 31, 2016 250,000.00
Dec 31, 2016 250,000.00
Sep 30, 2016 250,000.00
Sep 30, 2016 250,000.00
Jun 30, 2016 500,000.00
Jun 30, 2016 500,000.00
Dec 31, 2015 1.00 Mn
Dec 31, 2015 1.00 Mn
Sep 30, 2015 500,000.00
Sep 30, 2015 500,000.00
Mar 31, 2015 500,000.00
Mar 31, 2015 500,000.00
Dec 31, 2013 -884,764.00
Dec 31, 2013 -884,764.00
Mar 31, 2013 13,200.00
Mar 31, 2013 13,200.00